Review of tocilizumab in the treatment of rheumatoid arthritis

References

• ChoyEHIsenbergDAGarroodT2002Therapeutic benefit of blocking interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trialArthritis Rheum4631435012483717
   PubMed Web of Science ®Google Scholar
• FismanEZBenderlyMEsperRJ2006Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarctionAm J Cardiol98141816784912
   PubMed Web of Science ®Google Scholar
• HagiwaraKNishikawaTIsobeT2004IL-6 plays a critical role in synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay systemBiochem Biophys Res Commun314363914733913
   PubMed Web of Science ®Google Scholar
• HagiwaraKNishikawaKSugamataY2005Essential role of STAT3 in cytokine-driven NF-κB-mediated serum amyloid A gene expressionGene Cells10105163
   PubMed Web of Science ®Google Scholar
• HashimotoJGarneroPMiyasakaN2007Early changes in biochemical markers of cartilage turnover and synovial inflammation after tocilizumab monotherapy predict the one-year radiographic progression in patients with early rheumatoid arthritisMod Rheumatol17S78
   Google Scholar
• HiranoTYasukawaKHaradaH1986Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulinNature3247363491322
   PubMed Web of Science ®Google Scholar
• KiortsisDNMavridisAKFilippatosTD2006Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitisJ Rheumatol33921316541480
   PubMed Web of Science ®Google Scholar
• KotakeSSatoKKimKJ1996Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formationJ Bone Miner Res1188958770701
   PubMed Web of Science ®Google Scholar
• LubbertsEKoendersMIOppers-WalgreenB2004Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosionArthritis Rheum50650914872510
   PubMed Web of Science ®Google Scholar
• MainiRNTaylorPCSzechinskiJ2006Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateArthritis Rheum5428172916947782
   PubMed Web of Science ®Google Scholar
• MiharaMTakagiYTakedaY1998IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 miceClin Exp Immunol1123974029649207
   PubMed Web of Science ®Google Scholar
• MorganMEFliermanRvan DuivenvoordeLM2005Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cellsArthritis Rheum5222122115986351
   PubMed Web of Science ®Google Scholar
• NakaharaHSongJSugimotoM2003Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor (VEGF) production in rheumatoid arthritisArthritis Rheum481521912794819
   PubMed Web of Science ®Google Scholar
• NishimotoNMaedaKKuritaniT2003Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical studyJ Rheumatol3014263512858437
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaN2004Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum501761915188351
   PubMed Web of Science ®Google Scholar
• NishimotoNMiyasakaNYamamotoK2006aEfficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: results from a 24 week double-blind phase III studyAnn Rheum Dis65 Suppl II59
   Google Scholar
• NishimotoNMiyasakaNYamamotoK2006bConsistent clinical response resulted from three Japanese randomized controlled trials of tocilizumab, humanized anti-IL-6 receptor antibody, in active rheumatoid arthritis (RA) patientsArthritis Rheum54S410
   Google Scholar
• NishimotoNHashimotoJMiyasakaN2007Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumabAnn Rheum Dis661162717485422
   PubMed Web of Science ®Google Scholar
• OgawaJHarigaiMAkashiT2006Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibodyAnn Rheum Dis651667917105857
   PubMed Web of Science ®Google Scholar
• OkudaYTakasugiK2006Successful use of a humanized anti-interleukin-6 antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritisArthritis Rheum542997300016947531
   PubMed Web of Science ®Google Scholar
• OkudaYOhnishiMMatobaK2007Clinical evaluation of anti-cytokine therapies for AA amyloidosis complicating rheumatoid arthritis-in view of suppression of SAA levelsMod Rheumatol17S81
   PubMedGoogle Scholar
• RoachDRBeanAGDemangelC2002TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infectionJ Immunol1684620711971010
   PubMed Web of Science ®Google Scholar
• Roux-LombardPEberhardtKSaxneT2001Cytokines, metallo-proteinases, their inhibitors and cartilage oligometric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year studyRheumatology405445111371663
   PubMed Web of Science ®Google Scholar
• WardLDHowlettGJDiscoloG1994High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130J Biol Chem2692328698083235
   PubMed Web of Science ®Google Scholar
• YoshizakiKNakagawaTKaiedaT1982Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factorsJ Immunol12812963016799573
   PubMed Web of Science ®Google Scholar